Fermenta Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹133 Cr +1.9% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
FB

Fermenta Biotech Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Fermenta Biotech Q2 FY26: Capex ₹12 Cr

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹130Cr
+37% YoY
−4.4% QoQ
Net profit
₹18Cr
+62.1% YoY
−16.5% QoQ
Margin
20.46%
+0.7 pp YoY
−0.3 pp QoQ

Fermenta Biotech Ltd Q2 FY26 key numbers

Revenue
Q2FY26 Revenue: INR 135.7 crore, up 39% YoY.

As stated in Fermenta Biotech Ltd's Q2 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Fermenta Biotech Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹478
Market cap₹1.4K Cr
P/E25.5

The short version

Q2FY26 Revenue: INR 135.7 crore, up 39% YoY - H1FY26 Revenue: INR 280.7 crore, up 57% YoY - Human nutrition segment volumes grew 74% over H1FY25 - Animal nutrition segment volumes grew 6% over H Q2FY26 Financials: - EBITDA: ₹32.1 crore (up 48% YoY) - Profit after tax (PAT): ₹18.0 crore (up 62% YoY) - Revenue: ₹135.7 crore (up 39% YoY) - H1FY26 Financial Highlights: - EBITDA: ₹69.1 crore (up 173% YoY) - PAT: ₹39.6 crore (up 664% YoY) - Revenue: ₹280.7 crore (up 57% YoY) - EBITDA Margin: sustained at 25.9% for H1FY26 - Net Profit Margin: 14.9% in H1FY26 (from Performance Ratios on page 10) - Margin Outlook:

From Fermenta Biotech Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q2FY26 Revenue: INR 135.7 crore, up 39% YoY
  • H1FY26 Revenue: INR 280.7 crore, up 57% YoY
  • Human nutrition segment volumes grew 74% over H1FY25
  • Animal nutrition segment volumes grew 6% over H1FY25; average realization rose 35%

2 more points from Fermenta Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • H1FY26 investing cash flow shows ₹12 crore spent on Capex for growth initiatives (Page 8).
  • Only reference to "strategic capital investment" deployed for growth initiatives (Page 8).
  • In September 2025, the board approved the transfer of the Environment Division as a going concern to a wholly owned subsidiary for INR 19 crore; effective 1 October 2025 (Page 5).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.

Fermenta Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Fermenta Biotech Ltd Q2 FY26 results — key figures

Fermenta Biotech Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue13095+37%136-4.4%
Operating profit (EBITDA)2719+41.9%28-5.7%
Operating margin20.46%19.76%+0.7 pp20.73%-0.3 pp
Profit before tax2412+103.7%28-14.3%
Net profit (PAT)1811+62.1%22-16.5%
EPS (₹)6.143.87+58.7%7.42-17.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Fermenta Biotech Ltd Q2 FY26 results?

Q2FY26 Revenue: INR 135.7 crore, up 39% YoY - H1FY26 Revenue: INR 280.7 crore, up 57% YoY - Human nutrition segment volumes grew 74% over H1FY25 - Animal nutrition segment volumes grew 6% over H Q2FY26 Financials: - EBITDA: ₹32.1 crore (up 48% YoY) - Profit after tax (PAT): ₹18.0 crore (up 62% YoY) - Revenue: ₹135.7 crore (up 39% YoY) - H1FY26 Financial Highlights: - EBITDA: ₹69.1 crore (up 173% YoY) - PAT: ₹39.6 crore (up 664% YoY) - Revenue: ₹280.7 crore (up 57% YoY) - EBITDA Margin: sustained at 25.9% for H1FY26 - Net Profit Margin: 14.9% in H1FY26 (from Performance Ratios on page 10) - Margin Outlook:

What is Fermenta Biotech Ltd share price analysis?

Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fermenta Biotech Ltd planning capital expenditure?

H1FY26 investing cash flow shows ₹12 crore spent on Capex for growth initiatives (Page 8).

Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.